Search results for "marginal zone lymphoma"

showing 10 items of 33 documents

Distinctive Patterns of Intraclonal Diversification In IGHV1-2*04 Immunoglobulin Receptors of Patients with Splenic Marginal Zone Lymphoma: A of Ongo…

2011

Abstract Abstract 2638 We recently demonstrated that over 30% of cases with splenic marginal-zone lymphoma (SMZL) express distinctive immunoglobulin (IG) receptors that utilize a single polymorphic variant of the IGHV1-2 gene (IGHV1-2*04) and also exhibit restricted antigen-binding site motifs and precise targeting of somatic hypermutation (SHM). On these grounds, we proposed the existence of molecular subtypes of SMZL defined by immunogenetic analysis of the IG receptors with implications for selection by specific (super) antigenic element(s) in the development of at least a major subset of SMZL. In order to gain insight as to whether antigen involvement is relevant only prior to the malig…

GeneticsImmunologySomatic hypermutationCell BiologyHematologyComplementarity determining regionBiologymedicine.diseaseBiochemistryGermlineSubcloningmedicinebiology.proteinSplenic marginal zone lymphomaAntibodyIGHV@GeneBlood
researchProduct

Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome

2011

Abstract Marginal zone B-cell lymphomas (MZLs) have been divided into 3 distinct subtypes (extranodal MZLs of mucosa-associated lymphoid tissue [MALT] type, nodal MZLs, and splenic MZLs). Nevertheless, the relationship between the subtypes is still unclear. We performed a comprehensive analysis of genomic DNA copy number changes in a very large series of MZL cases with the aim of addressing this question. Samples from 218 MZL patients (25 nodal, 57 MALT, 134 splenic, and 2 not better specified MZLs) were analyzed with the Affymetrix Human Mapping 250K SNP arrays, and the data combined with matched gene expression in 33 of 218 cases. MALT lymphoma presented significantly more frequently gain…

MalePathologyLymphomaMarginal ZoneBiochemistryExtranodal Diseaseclassification/genetics/pathologyhemic and lymphatic diseases80 and overgeneticsAged 80 and overComparative Genomic HybridizationGenomeMALT lymphomaHematologySingle NucleotideMiddle AgedMarginal zonePrognosisGene Expression Regulation NeoplasticAdult Aged Aged; 80 and over Chromosome Aberrations Comparative Genomic Hybridization DNA Fingerprinting Female Gene Expression Profiling Gene Expression Regulation; Neoplastic Genome; Human Humans Lymphoma; B-Cell; Marginal Zone; classification/genetics/pathology Male Middle Aged Polymorphism; Single Nucleotide; genetics Prognosis Splenic Neoplasms; classification/genetics/pathology Young AdultFemaleHumanAdultmedicine.medical_specialtyGenome-wide DNA profilingImmunologyBiologyPolymorphism Single NucleotideYoung AdultGenome-wide DNA profiling; marginal zone lymphomas; clinical outcome.medicineSNPHumansSplenic marginal zone lymphomaPolymorphismAgedChromosome AberrationsNeoplasticGenome HumanSplenic Marginal Zone Lymphoma; GenomicGene Expression ProfilingSplenic NeoplasmsB-CellLymphoma B-Cell Marginal ZoneCell Biologyclinical outcome.medicine.diseasemarginal zone lymphomaDNA FingerprintingLymphomaGene expression profilingGene Expression RegulationComparative genomic hybridization
researchProduct

Splenectomy influences bone marrow infiltration in patients with splenic marginal zone cell lymphoma with or without villous lymphocytes.

2001

BACKGROUND Splenic marginal zone cell lymphoma (SMZL) is a low grade B-cell lymphoma in which patients can have circulating villous lymphocytes and can show a peculiar intrasinusoidal bone marrow (BM) infiltration. Splenectomy is the reported treatment of choice for these patients. The objective of this study was to evaluate the effects of splenectomy on patients with BM lymphomatous infiltration. METHODS BM biopsies of 16 patients with SMZL were studied morphologically and immunohistochemically. In 12 patients, BM biopsies were taken before and after splenectomy. Four patients did not undergo splenectomy, and their BM biopsies were performed with an approximately 1 year interval. RESULTS B…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyLymphoma B-Cellmedicine.medical_treatmentSplenectomySpleenLymphocytosisBone MarrowmedicineHumansIn patientSplenic marginal zone lymphomaAgedbusiness.industryLymphoma Non-HodgkinSplenic lymphoma with villous lymphocytesMiddle Agedmedicine.diseaseLymphomamedicine.anatomical_structureOncologySplenectomyFemaleBone marrowbusinessInfiltration (medical)Cancer
researchProduct

Over 30% of Patients with Splenic Marginal Zone Lymphoma Express Distinctive Antigen Receptors Utilizing a Single Immunoglogulin Variable Gene: Impli…

2010

Abstract Abstract 634 We systematically explored the immunoglobulin (IG) gene repertoire in 337 cases with splenic marginal-zone lymphoma (SMZL), by far the largest series yet. To resolve classification uncertainties, we included in the analysis only cases with a diagnosis of SMZL based on spleen histopathological findings or cases fulfilling the 2008 SBLG criteria (Matutes et al. Leukemia 2008). We here report that the IG heavy variable (IGHV) gene repertoire in SMZL is remarkably biased, with only three genes accounting for 45.8% of cases (IGHV1-2, 24.9%; IGHV4-34, 12.8%; IGHV3-23: 8.1%, respectively), significantly extending previous similar observations. Particularly for the IGHV1-2 gen…

GeneticsImmunologyCell BiologyHematologyBiologymedicine.diseaseBiochemistryLymphomamedicine.anatomical_structureImmunologymedicineRed pulpSplenic marginal zone lymphomaAlleleFramework regionIGHV@GeneDominance (genetics)
researchProduct

Successful Treatment of Catastrophic Antiphospholipid Antibody Syndrome (CAPS) Associated With Splenic Marginal-zone Lymphoma With Low-molecular Weig…

2008

ABSTRACT Case report A 69-year-old woman with splenic marginal-zone lymphoma was admitted with progressive abdominal pain and splenomegaly as the suspected cause of pain. Rituximab treatment (375 mg/m 2 ) had been initiated on the day of admission. Abdominal computerized tomography revealed splenic infarction. Laboratory tests showed elevation of liver enzymes and creatinine, low platelet count, prolonged partial thromboplastin time, and lupus anticoagulant positivity. The diagnosis of catastrophic antiphospholipid antibody syndrome was made. Weight-adjusted low-molecular weight heparin therapy was initiated. Freedom from symptoms and normalization of liver enzymes and creatinine occurred w…

Bendamustinemedicine.medical_specialtyLymphoma B-Cellmedicine.drug_classLow molecular weight heparinAntineoplastic AgentsGastroenterologyAntibodies Monoclonal Murine-Derivedimmune system diseaseshemic and lymphatic diseasesInternal medicineBendamustine HydrochlorideHumansMedicineSplenic marginal zone lymphomaAgedLupus anticoagulantbusiness.industrySplenic NeoplasmsAnticoagulantAntibodies MonoclonalAnticoagulantsGeneral MedicineHeparinHeparin Low-Molecular-WeightAntiphospholipid Syndromemedicine.diseaseSurgerySplenic infarctionNitrogen Mustard CompoundsFemaleRituximabRituximabbusinessmedicine.drugThe American Journal of the Medical Sciences
researchProduct

Splenic marginal zone lymphoma with or without villous lymphocytes

2004

The Integruppo Italiano Linfomi (IIL) carried out a study to assess the outcomes of splenic marginal zone lymphoma and to identify prognostic factors in 309 patients. The 5-year cause-specific survival (CSS) rate was 76%. In univariate analysis, the parameters predictive of shorter CSS were hemoglobin levels below 12 g/dL (P < .001), albumin levels below 3.5 g/dL (P = .001), International Prognostic Index (IPI) scores of 2 to 3 (P < .001), lactate dehydrogenase (LDH) levels above normal (P < .001), age older than 60 years (P = .01), platelet counts below 100,000/microL (P = .04), HbsAg-positivity (P = .01), and no splenectomy at diagnosis (P = .006). Values that maintained a negative influe…

Splenic marginal zone lymphoma
researchProduct

Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications.

2012

We performed an immunogenetic analysis of 345 IGHV-IGHD-IGHJ rearrangements from 337 cases with primary splenic small B-cell lymphomas of marginal-zone origin. Three immunoglobulin (IG) heavy variable (IGHV) genes accounted for 45.8% of the cases (IGHV1-2, 24.9%; IGHV4-34, 12.8%; IGHV3-23, 8.1%). Particularly for the IGHV1-2 gene, strong biases were evident regarding utilization of different alleles, with 79/86 rearrangements (92%) using allele *04. Among cases more stringently classified as splenic marginal-zone lymphoma (SMZL) thanks to the availability of splenic histopathological specimens, the frequency of IGHV1-2*04 peaked at 31%. The IGHV1-2*04 rearrangements carried significantly lo…

Immunoglobulin geneModels MolecularCancer ResearchGenes Immunoglobulin Heavy ChainGene Rearrangement B-Lymphocyte Heavy ChainImmunoglobulin Variable RegionSomatic hypermutationSplenic NeoplasmBiologyCohort StudiesantigenmedicineHumansSplenic marginal zone lymphomaAlleleGeneticsSplenic Neoplasmssplenic marginal-zone lymphomaHematologyGene rearrangementLymphoma B-Cell Marginal Zonemedicine.diseasePrognosisComplementarity Determining Regionssomatic hypermutationimmunoglobulin geneOncologyMutationIGHDsplenic marginal-zone lymphoma; immunoglobulin gene; somatic hypermutation; CDR3; antigenCDR3IGHV@Leukemia
researchProduct

Reply to Pich et al.: intrasinusoidal bone marrow infiltration and splenic marginal zone lymphoma: a quantitative study

2006

Pathologymedicine.medical_specialtybone marrowsplenic marginal zone lymphoma.Bone marrow infiltrationbusiness.industryintrasinusoidalHematologyGeneral Medicineinfiltrationmedicine.diseaseMedicineSplenic marginal zone lymphomabusinessEuropean Journal of Haematology
researchProduct

Assessment of the frequency of additional cancers in patients with splenic marginal zone lymphoma

2006

Abstract: Objectives: Solid second primary cancers (SPC) have become an issue of extensive research. The purpose of the present study was to estimate the standardised incidence ratio (SIR) and the absolute excess risk (AER) of SPC in patients with splenic marginal zone lymphoma (SMZL). Methods: We investigated the incidence of additional cancers in 129 patients consecutively diagnosed with SMZL in three Italian haematological centres, asking the cooperating doctors for additional information on initial and subsequent therapies and on the onset and type of second cancers. Results: Twelve SPC were recorded (9.3%); the 3- and 5-yr cumulative incidence rates were 5.5% and 18.3% respectively, wi…

Oncologymedicine.medical_specialtyLymphomaPopulationsplenic marginal zone lymphomaBreast cancerInternal medicinemedicinecancerHumansCumulative incidenceSplenic marginal zone lymphomaLung cancereducationAgededucation.field_of_studysplenic marginal zone lymphoma cancerbusiness.industryIncidenceSplenic Neoplasmsadditional cancerCancerNeoplasms Second PrimarySplenic lymphoma with villous lymphocytesHematologyGeneral MedicineMiddle Agedmedicine.diseaseNon-Hodgkin's lymphomabusinessEuropean Journal of Haematology
researchProduct

Immunophenotypic profile and role of adhesion molecules in splenic marginal zone lymphoma with bone marrow involvement

2005

Abstract Splenic Marginal Zone Lymphoma (SMZL), with or without villous lymphocytes (VL+/-), is a low-grade lymphoproliferative disorder with constant involvement of the bone marrow (BM). Different BM infiltration patterns, mainly intra-sinusoidal, interstitial and nodular, have been described. Adhesion molecules (AMs) constitute a heterogeneous group of antigenic receptors playing a major role in leukocyte recruitment, in lymphocyte homing and in cellular-mediated immune response. Evolution and pattern of the BM infiltrate could be influenced by a variable expression of AM on SMZL lymphocytes. The degree and pattern of BM infiltration and the immunohistochemical expression of AM (H-CAM, BL…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyLymphomasplenic marginal zone lymphomaBiologyImmunophenotypingAntigenAntigens NeoplasmBone MarrowmedicineHumansLymphocytesSplenic marginal zone lymphomabone marrow involvementLymphocyte homing receptorAgedCell adhesion moleculeSplenic NeoplasmsHematologyMiddle Agedrole of adhesion moleculemedicine.diseaseImmunophenotypic profilemedicine.anatomical_structureOncologyReticular connective tissueImmunohistochemistryFemaleBone marrowCell Adhesion MoleculesInfiltration (medical)
researchProduct